Autopsy report · NCT03759041

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

“Due to the lack of a clinical efficacy signal in the induction treatment phase, Seres closed the dosing phases of open label and maintenance portions of the study. Patients who had received prior doses were followed for safety data.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 10 months before it stopped.
• 203 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Seres Therapeutics, Inc.

Sponsor type

Industry

Conditions

Ulcerative Colitis

Interventions

Vancomycin Pre-Treatment; Placebo for Vancomycin Pre-Treatment; SER-287; Placebo for SER-287

Participants

203

Sites

93

Countries

Canada, United States

Trials that died the same way

• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  “Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.